J Acquir Immune Defic Syndr. 2022 Dec 12. doi: 10.1097/QAI.0000000000003145. Online ahead of print.
ABSTRACT
BACKGROUND: To collect and compare selected hearing measures in a pilot study of young adults with perinatally-acquired HIV (YAPHIV), and those with perinatal HIV-exposure, who are uninfected (YAPHEU).
SETTING: Cross-sectional hearing measures in YAPHIV and YAPHEU enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) for Participants 18 Years of Age and Older (AMP Up).
METHODS: Pure-tone air conduction audiometry and distortion product otoacoustic emission (DPOAE) data were collected in one visit. A low-frequency pure-tone average (PTA) (LFPTA, at 0.25, 0.5, 1, and 2 kHz), a speech-frequency PTA (SFPTA, at 0.5, 1, 2, and 4 kHz), and a high-frequency PTA (HFPTA, at 3, 4, 6, and 8 kHz) were calculated. Hearing loss was defined as worse ear SFPTA ≥20 dB HL. Separate linear regression models were fit for worse ear LFPTA, SFPTA, and HFPTA to assess associations with PHIV status. DPOAE signal-to-noise ratios (SNRs) were obtained at three frequencies in each ear.
RESULTS: Forty-seven YAPHIV and 9 YAPHEU completed hearing testing. All adjusted mean PTAs were similar between YAPHIV and YAPHEU. Hearing loss occurred more in YAPHIV (7/47, 15.2%, 95% CI: 6.3%-28.9%), compared to YAPHEU (0/9, 0%). No associations were detected between HIV disease severity measures and worse ear SFPTA. DPOAE SNRs were similar between YAPHIV and YAPHEU.
CONCLUSIONS: In this pilot study, peripheral hearing (i.e., PTAs) and cochlear function (i.e., DPOAEs) were similar between YAPHIV and YAPHEU. A larger study is warranted to confirm these findings.
PMID:36729663 | DOI:10.1097/QAI.0000000000003145
